In lung adenocarcinoma, where intrinsic radioresistance remains a major obstacle to treatment success, PARP inhibition offers a rational approach to amplify the cytotoxic effects of radiotherapy [22,23]. The gene discussed is PARP1; the disease is lung adenocarcinoma.